

Veterinary Ophthalmic Drugs Market Size, Share and Growth Outlook 2026: By Drug Class, By Animal Type, By Indication, By Distribution Channel, Companies to 2034

<https://marketpublishers.com/r/VB25B10B2F75EN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: VB25B10B2F75EN

Abstracts

The global Veterinary Ophthalmic Drugs Market size is forecast to increase from \$2.2 Billion in 2026 to \$3.84 Billion in 2034 at a CAGR of 7.21% between 2026 and 2034.

The Veterinary Ophthalmic Drugs market report provides detailed analysis and outlook of Veterinary Ophthalmic Drugs segments including By Drug Class (Lubricants / Artificial Tears, Antibiotics, Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Analgesics / Pain Relievers, Other Drugs), By Animal Type (Canine, Feline, Equine, Bovine, Other Animal Types), By Indication (Conjunctivitis, Corneal Complications, Glaucoma, Cataracts, Uveitis, Eyelid Abnormalities, Retinal Complications, Other Indications), By Distribution Channel (Veterinary Hospitals and Clinics, E-Commerce, Pet Specialty Stores, Other Distribution Channels) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Veterinary Ophthalmic Drugs Industry Overview

Advanced ocular therapeutics, regulatory compliance, and formulation innovation are strengthening veterinary ophthalmic care.

The global veterinary ophthalmic drugs industry is advancing through the development of specialized therapies that improve ocular surface healing, long-term eye hydration, infection management, and treatment safety across companion and large animals.

Manufacturers are expanding preservative-free formulations, hyaluronic acid-based technologies, and targeted ophthalmic products designed to address corneal disease, dry eye, and bacterial infections. At the same time, regulatory authorities are reinforcing manufacturing quality, sterility standards, and product oversight to ensure the safety and effectiveness of topical veterinary eye medications.

Innovative ocular therapies are expanding treatment options for companion animals.

The market is increasingly focused on advanced formulations that accelerate tissue repair while improving long-term management of chronic ophthalmic disorders. D?mes Pharma strengthened its North American presence by rebranding SentrX Animal Care as D?mes Pharma, Inc. and expanding distribution of its ophthalmic portfolio following the acquisition of the NeoPolyBac veterinary ophthalmic ointment brand from Akorn Pharmaceuticals. The broader portfolio combines established anti-infective therapy with BioHAnce™ hyaluronic acid technology, including Oculenis®, a preservative-free ocular barrier gel developed to promote healing in canine corneal ulcers, and Ocunovis®, a long-acting hydration gel formulated for chronic keratoconjunctivitis sicca (dry eye). These developments reflect the industry's transition toward multifunctional ophthalmic therapies that support both disease treatment and ocular surface regeneration.

Quality assurance and regulatory oversight are reinforcing product safety.

Manufacturers and regulators continue to strengthen quality systems to minimize contamination risks and improve confidence in veterinary ophthalmic medicines. Dechra Pharmaceuticals PLC initiated a voluntary wholesaler-level recall of selected batches of Ophthocycline eye ointment following a precautionary alert issued by the UK Veterinary Medicines Directorate (VMD) regarding potential microbial contamination linked to a third-party aseptic manufacturing process. Complementing these regulatory actions, the U.S. Food and Drug Administration Center for Veterinary Medicine (CVM) updated Good Manufacturing Practice (GMP) guidance for active pharmaceutical ingredients used in veterinary ophthalmic products, introducing stricter environmental controls, packaging integrity requirements, and preservation standards for topical eye drops and ointments. These measures highlight the industry's continued emphasis on manufacturing excellence, sterility assurance, and patient safety across veterinary ophthalmology.

Veterinary Ophthalmic Drugs Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Veterinary Ophthalmic Drugs market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Zoetis Inc., Boehringer Ingelheim International GmbH, Merck Animal Health (MSD), Elanco Animal Health Incorporated, Virbac, Dechra Pharmaceuticals PLC, Vetoquinol SA, Ceva Santé Animale, Bausch + Lomb, Akorn Operating Company LLC. The Veterinary Ophthalmic Drugs market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Veterinary Ophthalmic Drugs industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

Growth Veterinary Ophthalmic Drugs Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

Market Trends, Drivers, Potential Opportunities, and Challenges faced by Veterinary Ophthalmic Drugs companies

Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

Detailed SWOT Analysis of global and regional Veterinary Ophthalmic Drugs markets

Competitive analysis including business description, product analysis, and financial profiles

Key country specific analysis detailing key factors shaping the short-term and long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Veterinary Ophthalmic Drugs Market Competitive Benchmarking and Company Analysis

Veterinary Ophthalmic Drugs Market Size, Share and Growth Outlook 2026: By Drug Class, By Animal Type, By Indi...

Leading companies in Veterinary Ophthalmic Drugs industry include- Zoetis Inc., Boehringer Ingelheim International GmbH, Merck Animal Health (MSD), Elanco Animal Health Incorporated, Virbac, Dechra Pharmaceuticals PLC, Vetoquinol SA, Ceva Santé Animale, Bausch + Lomb, Akorn Operating Company LLC. The Veterinary Ophthalmic Drugs market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Veterinary Ophthalmic Drugs Markets in 2026 and beyond-
Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Veterinary Ophthalmic Drugs market remains one of the strongest-performing segments in the country.

The US Veterinary Ophthalmic Drugs Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Veterinary Ophthalmic Drugs market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Veterinary Ophthalmic Drugs industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Veterinary Ophthalmic Drugs markets

Canada's strong Veterinary Ophthalmic Drugs sales performance is underpinned by an

aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Veterinary Ophthalmic Drugs market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Veterinary Ophthalmic Drugs Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Veterinary Ophthalmic Drugs market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Veterinary Ophthalmic Drugs population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Veterinary Ophthalmic Drugs industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Veterinary Ophthalmic Drugs market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Veterinary Ophthalmic Drugs sales through 2034

France Veterinary Ophthalmic Drugs companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care

establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Veterinary Ophthalmic Drugs Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Veterinary Ophthalmic Drugs distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Veterinary Ophthalmic Drugs Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Veterinary Ophthalmic Drugs market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Veterinary Ophthalmic Drugs industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Veterinary Ophthalmic Drugs industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Veterinary Ophthalmic Drugs Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Veterinary Ophthalmic Drugs market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Veterinary Ophthalmic Drugs market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Veterinary Ophthalmic Drugs Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Veterinary Ophthalmic Drugs Market Segmentation

By Drug Class

Lubricants / Artificial Tears

Antibiotics

Corticosteroids

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

Analgesics / Pain Relievers

Other Drugs

By Animal Type

Canine

Feline

Equine

Bovine

Other Animal Types

By Indication

Conjunctivitis

Corneal Complications

Glaucoma

Cataracts

Uveitis

Eyelid Abnormalities

Retinal Complications

Other Indications

By Distribution Channel

Veterinary Hospitals and Clinics

E-Commerce

Pet Specialty Stores

Other Distribution Channels

Leading Companies in Veterinary Ophthalmic Drugs Industry (2026)

Zoetis Inc.

Boehringer Ingelheim International GmbH

Merck Animal Health (MSD)

Elanco Animal Health Incorporated

Virbac

Dechra Pharmaceuticals PLC

Vetoquinol SA

Ceva Santé Animale

Bausch + Lomb

Akorn Operating Company LLC

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Veterinary Ophthalmic Drugs Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Veterinary Ophthalmic Drugs Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL VETERINARY OPHTHALMIC DRUGS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Veterinary Ophthalmic Drugs Markets in 2026
- 3.2. Global Historic and Forecast Veterinary Ophthalmic Drugs Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics
 - 3.4.1. Key Veterinary Ophthalmic Drugs Market Driving Forces and Their Impact on

Market Outlook

3.4.2. Short and Long-Term Trends and Insights Shaping the Future

3.4.3. Potential Veterinary Ophthalmic Drugs Market Opportunities for Industry Stakeholders

3.4.4. Potential Challenges across Veterinary Ophthalmic Drugs Value Chain

CHAPTER 4- VETERINARY OPHTHALMIC DRUGS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

4.1. Porter's Five Forces Analysis

4.1.1. Bargaining Power of Buyers

4.1.2. Bargaining Power of Suppliers

4.1.3. Threat of Substitutes

4.1.4. Threat of New Entrants

4.1.5. Intensity of Competitive Rivalry

4.1.6. Market Attractiveness Analysis by Segment

4.1.7. Market Attractiveness Analysis by Region

4.2. Competitive Landscape

4.2.1 Market Share Analysis of Leading Veterinary Ophthalmic Drugs Companies

4.2.2 Recent Strategic Developments

4.2.3 Mergers, Acquisitions, and Partnerships

4.2.4 Product Launches and Innovation Trends

4.2.5 Key Success Factors

4.3. Value Chain Analysis

4.3.1. Key Value Chain Segments

4.3.2. Dominant players by value-chain stage

4.4. SWOT Analysis

4.4.1. Key Strengths and Opportunities

4.4.2. Major Weaknesses and Threats

4.5 Technology Roadmap

4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- VETERINARY OPHTHALMIC DRUGS MARKET OUTLOOK BY SEGMENTS

5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034

5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034

5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034

By Drug Class

Lubricants / Artificial Tears
Antibiotics
Corticosteroids
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Analgesics / Pain Relievers
Other Drugs
By Animal Type
Canine
Feline
Equine
Bovine
Other Animal Types
By Indication
Conjunctivitis
Corneal Complications
Glaucoma
Cataracts
Uveitis
Eyelid Abnormalities
Retinal Complications
Other Indications
By Distribution Channel
Veterinary Hospitals and Clinics
E-Commerce
Pet Specialty Stores
Other Distribution Channels

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA VETERINARY OPHTHALMIC DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

- 7.1. North America Veterinary Ophthalmic Drugs Market Overview, 2026
- 7.2. Leading Companies Operating in North America
- 7.3. Key Industry Statistics, 2026
- 7.4. North America Veterinary Ophthalmic Drugs Market Trends and Growth Opportunities to 2034
- 7.5. North America Veterinary Ophthalmic Drugs Market Size Outlook by Type
- 7.6. North America Veterinary Ophthalmic Drugs Market Size Outlook by Application
- 7.7. North America Veterinary Ophthalmic Drugs Market Size Outlook by Country
- 7.8. United States
 - 7.8.1. Key Statistics
 - 7.8.2. The US Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 7.8.3. Key Market Drivers and Industry Developments in the US Veterinary Ophthalmic Drugs Companies
- 7.9. Canada
 - 7.9.1. Key Statistics
 - 7.9.2. Canada Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 7.9.3. Key Market Drivers and Industry Developments in Canada Veterinary Ophthalmic Drugs Companies
- 7.10. Mexico
 - 7.10.1. Key Statistics
 - 7.10.2. Mexico Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 7.10.3. Key Market Drivers and Industry Developments in Mexico Veterinary Ophthalmic Drugs Companies

CHAPTER 8- EUROPE VETERINARY OPHTHALMIC DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

- 8.1. Europe Veterinary Ophthalmic Drugs Market Overview, 2026
- 8.2. Leading Companies Operating in Europe
- 8.3. Key Industry Statistics, 2026
- 8.4. Europe Veterinary Ophthalmic Drugs Market Trends and Growth Opportunities to 2034
- 8.5. Europe Veterinary Ophthalmic Drugs Market Size Outlook by Type
- 8.6. Europe Veterinary Ophthalmic Drugs Market Size Outlook by Application
- 8.7. Europe Veterinary Ophthalmic Drugs Market Size Outlook by Country
- 8.8. Germany

- 8.8.1. Key Statistics
- 8.8.2. Germany Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
- 8.8.3. Key Market Drivers and Industry Developments in Germany Veterinary Ophthalmic Drugs Companies
- 8.9. France
 - 8.9.1. Key Statistics
 - 8.9.2. France Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 8.9.3. Key Market Drivers and Industry Developments in France Veterinary Ophthalmic Drugs Companies
- 8.10. United Kingdom
 - 8.10.1. Key Statistics
 - 8.10.2. United Kingdom Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 8.10.3. Key Market Drivers and Industry Developments in the UK Veterinary Ophthalmic Drugs Companies
- 8.11. Spain
 - 8.11.1. Key Statistics
 - 8.11.2. Spain Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 8.11.3. Key Market Drivers and Industry Developments in Spain Veterinary Ophthalmic Drugs Companies
- 8.12. Italy
 - 8.12.1. Key Statistics
 - 8.12.2. Italy Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 8.12.3. Key Market Drivers and Industry Developments in Italy Veterinary Ophthalmic Drugs Companies
- 8.13. Rest of Europe
 - 8.13.1. Key Statistics
 - 8.13.2. Rest of Europe Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Veterinary Ophthalmic Drugs Companies

CHAPTER 9- ASIA PACIFIC VETERINARY OPHTHALMIC DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

- 9.1. Asia Pacific Veterinary Ophthalmic Drugs Market Overview, 2026
- 9.2. Leading Companies Operating in Asia Pacific
- 9.3. Key Industry Statistics, 2026
- 9.4. Asia Pacific Veterinary Ophthalmic Drugs Market Trends and Growth Opportunities to 2034

- 9.5. Asia Pacific Veterinary Ophthalmic Drugs Market Size Outlook by Type
- 9.6. Asia Pacific Veterinary Ophthalmic Drugs Market Size Outlook by Application
- 9.7. Asia Pacific Veterinary Ophthalmic Drugs Market Size Outlook by Country
- 9.8. China
 - 9.8.1. Key Statistics
 - 9.8.2. China Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 9.8.3. Key Market Drivers and Industry Developments in China Veterinary Ophthalmic Drugs Companies
- 9.9. Japan
 - 9.9.1. Key Statistics
 - 9.9.2. Japan Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 9.9.3. Key Market Drivers and Industry Developments in Japan Veterinary Ophthalmic Drugs Companies
- 9.10. India
 - 9.10.1. Key Statistics
 - 9.10.2. India Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 9.10.3. Key Market Drivers and Industry Developments in India Veterinary Ophthalmic Drugs Companies
- 9.11. South Korea
 - 9.11.1. Key Statistics
 - 9.11.2. South Korea Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 9.11.3. Key Market Drivers and Industry Developments in South Korea Veterinary Ophthalmic Drugs Companies
- 9.12. Australia
 - 9.12.1. Key Statistics
 - 9.12.2. Australia Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 9.12.3. Key Market Drivers and Industry Developments in Australia Veterinary Ophthalmic Drugs Companies
- 9.13. Southeast Asia
 - 9.13.1. Key Statistics
 - 9.13.2. Southeast Asia Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034
 - 9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Veterinary Ophthalmic Drugs Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA VETERINARY OPHTHALMIC DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

- 10.1. South and Central America Veterinary Ophthalmic Drugs Market Overview, 2026
- 10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Veterinary Ophthalmic Drugs Market Trends and Growth Opportunities to 2034

10.5. South and Central America Veterinary Ophthalmic Drugs Market Size Outlook by Type

10.6. South and Central America Veterinary Ophthalmic Drugs Market Size Outlook by Application

10.7. South and Central America Veterinary Ophthalmic Drugs Market Size Outlook by Country

10.8. Brazil

10.8.1. Key Statistics

10.8.2. Brazil Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034

10.8.3. Key Market Drivers and Industry Developments in Brazil Veterinary Ophthalmic Drugs Companies

10.9. Argentina

10.9.1. Key Statistics

10.9.2. Argentina Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034

10.9.3. Key Market Drivers and Industry Developments in Argentina Veterinary Ophthalmic Drugs Companies

10.10. Rest of Latin America

10.10.1. Key Statistics

10.10.2. Rest of Latin America Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034

10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Veterinary Ophthalmic Drugs Companies

CHAPTER 11- MIDDLE EAST AND AFRICA VETERINARY OPHTHALMIC DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

11.1. Middle East and Africa Veterinary Ophthalmic Drugs Market Overview, 2026

11.2. Leading Companies Operating in Middle East and Africa

11.3. Key Industry Statistics, 2026

11.4. Middle East and Africa Veterinary Ophthalmic Drugs Market Trends and Growth Opportunities to 2034

11.5. Middle East and Africa Veterinary Ophthalmic Drugs Market Size Outlook by Type

11.6. Middle East and Africa Veterinary Ophthalmic Drugs Market Size Outlook by Application

11.7. Middle East and Africa Veterinary Ophthalmic Drugs Market Size Outlook by Country

11.8. Saudi Arabia

11.8.1. Key Statistics

11.8.2. Saudi Arabia Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034

11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Veterinary Ophthalmic Drugs Companies

11.9. United Arab Emirates

11.9.1. Key Statistics

11.9.2. The UAE Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034

11.9.3. Key Market Drivers and Industry Developments in the UAE Veterinary Ophthalmic Drugs Companies

11.10. Africa

11.10.1. Key Statistics

11.10.2. Africa Veterinary Ophthalmic Drugs Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Veterinary Ophthalmic Drugs Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Veterinary Ophthalmic Drugs Industry

Zoetis Inc.

Boehringer Ingelheim International GmbH

Merck Animal Health (MSD)

Elanco Animal Health Incorporated

Virbac

Dechra Pharmaceuticals PLC

Vetoquinol SA

Ceva Santé Animale

Bausch + Lomb

Akorn Operating Company LLC

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Veterinary Ophthalmic Drugs Market Size, Share and Growth Outlook 2026: By Drug Class, By Animal Type, By Indication, By Distribution Channel, Companies to 2034

Product link: <https://marketpublishers.com/r/VB25B10B2F75EN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VB25B10B2F75EN.html>